Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C22H43N5O13 |
Molecular Weight | 585.6025 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 16 / 16 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@]3(O[C@H]1[C@@H](C[C@H](N)[C@@H](O[C@@]2([H])O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@@H]1O)NC(=O)[C@@H](O)CCN)O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O
InChI
InChIKey=LKCWBDHBTVXHDL-RMDFUYIESA-N
InChI=1S/C22H43N5O13/c23-2-1-8(29)20(36)27-7-3-6(25)18(39-22-16(34)15(33)13(31)9(4-24)37-22)17(35)19(7)40-21-14(32)11(26)12(30)10(5-28)38-21/h6-19,21-22,28-35H,1-5,23-26H2,(H,27,36)/t6-,7+,8-,9+,10+,11-,12+,13+,14+,15-,16+,17-,18+,19-,21+,22+/m0/s1
Molecular Formula | C22H43N5O13 |
Molecular Weight | 585.6025 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 16 / 16 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6ec3129b-c53b-4bdb-913d-a2d0060fa140Curator's Comment: Description was created based on several sources, including http://www.drugbank.ca/drugs/DB00479
Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6ec3129b-c53b-4bdb-913d-a2d0060fa140
Curator's Comment: Description was created based on several sources, including http://www.drugbank.ca/drugs/DB00479
Amikacin, USP (as the sulfate) is a semi-synthetic aminoglycoside antibiotic derived from kanamycin. Amikacin "irreversibly" binds to specific 30S-subunit proteins and 16S rRNA. Amikacin inhibits protein synthesis by binding to the 30S ribosomal subunit to prevent the formation of an initiation complex with messenger RNA. Specifically Amikacin binds to four nucleotides of 16S rRNA and a single amino acid of protein S12. This interferes with decoding site in the vicinity of nucleotide 1400 in 16S rRNA of 30S subunit. This region interacts with the wobble base in the anticodon of tRNA. This leads to interference with the initiation complex, misreading of mRNA so incorrect amino acids are inserted into the polypeptide leading to nonfunctional or toxic peptides and the breakup of polysomes into nonfunctional monosomes. Amikacin is used for short-term treatment of serious infections due to susceptible strains of Gram-negative bacteria, including Pseudomonas species, Escherichia coli, species of indole-positive and indole-negative Proteus, Providencia species, Klebsiella-Enterobacter-Serratia species, and Acinetobacter (Mima-Herellea) species. Amikacin may also be used to treat Mycobacterium avium and Mycobacterium tuberculosis infections. Amikacin was used for the treatment of gram-negative pneumonia.
CNS Activity
Originator
Sources: http://www.tmfile.com/mark/?q=731096386
Curator's Comment: # Bristol-Myers Squibb
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1641336 Sources: http://www.drugbank.ca/drugs/DB00479 |
5.27 mM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Sources: http://www.ncbi.nlm.nih.gov/pubmed/868912 |
Curative | Unknown Approved UseUnknown |
||
Primary | Unknown Approved UseUnknown |
|||
Curative | AMIKACIN SULFATE Approved UseAmikacin sulfate injection is indicated in the short-term treatment of serious infections due to susceptible strains of Gram-negative bacteria, including Pseudomonas species, Escherichia coli, species of indole-positive and indole-negative Proteus, Providencia species, Klebsiella-Enterobacter-Serratia species, and Acinetobacter (Mima-Herellea) species. Amikacin sulfate is effective in bacterial septicemia (including neonatal sepsis). Launch Date7.4917439E11 |
|||
Curative | AMIKACIN SULFATE Approved UseAmikacin sulfate injection is indicated in the short-term treatment of serious infections due to susceptible strains of Gram-negative bacteria, including Pseudomonas species, Escherichia coli, species of indole-positive and indole-negative Proteus, Providencia species, Klebsiella-Enterobacter-Serratia species, and Acinetobacter (Mima-Herellea) species. Amikacin sulfate is effective in central nervous system infections (including meningitis) Launch Date7.4917439E11 |
|||
Curative | AMIKACIN SULFATE Approved UseAmikacin sulfate injection is indicated in the short-term treatment of serious infections due to susceptible strains of Gram-negative bacteria, including Pseudomonas species, Escherichia coli, species of indole-positive and indole-negative Proteus, Providencia species, Klebsiella-Enterobacter-Serratia species, and Acinetobacter (Mima-Herellea) species. Amikacin sulfate is effective in serious complicated and recurrent urinary tract infections due to these organisms. Launch Date7.4917439E11 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2.8 μg/mL |
590 mg 1 times / day steady-state, respiratory dose: 590 mg route of administration: Respiratory experiment type: STEADY-STATE co-administered: |
AMIKACIN serum | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
23.5 μg × h/mL |
590 mg 1 times / day steady-state, respiratory dose: 590 mg route of administration: Respiratory experiment type: STEADY-STATE co-administered: |
AMIKACIN serum | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
5.9 h |
590 mg 1 times / day steady-state, respiratory dose: 590 mg route of administration: Respiratory experiment type: STEADY-STATE co-administered: |
AMIKACIN serum | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
90% |
590 mg 1 times / day steady-state, respiratory dose: 590 mg route of administration: Respiratory experiment type: STEADY-STATE co-administered: |
AMIKACIN serum | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
15 mg/kg single, intravenous Highest studied dose Dose: 15 mg/kg Route: intravenous Route: single Dose: 15 mg/kg Sources: |
healthy, 21-30 years n = 6 Health Status: healthy Age Group: 21-30 years Population Size: 6 Sources: |
|
60 mg/kg single, respiratory Highest studied dose Dose: 60 mg/kg Route: respiratory Route: single Dose: 60 mg/kg Sources: |
healthy, 21-30 years n = 6 Health Status: healthy Age Group: 21-30 years Population Size: 6 Sources: |
|
590 mg 1 times / day multiple, respiratory Recommended Dose: 590 mg, 1 times / day Route: respiratory Route: multiple Dose: 590 mg, 1 times / day Sources: |
unhealthy, 58.0 years (range: 16 - 61 years) n = 44 Health Status: unhealthy Age Group: 58.0 years (range: 16 - 61 years) Sex: M+F Population Size: 44 Sources: |
Disc. AE: Infective exacerbation of bronchiectasis, Dyspnea... AEs leading to discontinuation/dose reduction: Infective exacerbation of bronchiectasis (6.8%) Sources: Dyspnea (4.5%) Cough (1 patient) Oropharyngeal pain (1 patient) Respiratory disorder (1 patient) Pneumonia (1 patient) |
15 mg/kg 1 times / day multiple, intramuscular Highest studied dose Dose: 15 mg/kg, 1 times / day Route: intramuscular Route: multiple Dose: 15 mg/kg, 1 times / day Sources: |
unhealthy, adult n = 15 Health Status: unhealthy Condition: pulmonary tuberculosis Age Group: adult Population Size: 15 Sources: |
|
590 mg 1 times / day multiple, respiratory Recommended Dose: 590 mg, 1 times / day Route: respiratory Route: multiple Dose: 590 mg, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Other AEs: Hypersensitivity pneumonitis, Hemoptysis... Other AEs: Hypersensitivity pneumonitis Sources: Hemoptysis Bronchospasm |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Cough | 1 patient Disc. AE |
590 mg 1 times / day multiple, respiratory Recommended Dose: 590 mg, 1 times / day Route: respiratory Route: multiple Dose: 590 mg, 1 times / day Sources: |
unhealthy, 58.0 years (range: 16 - 61 years) n = 44 Health Status: unhealthy Age Group: 58.0 years (range: 16 - 61 years) Sex: M+F Population Size: 44 Sources: |
Oropharyngeal pain | 1 patient Disc. AE |
590 mg 1 times / day multiple, respiratory Recommended Dose: 590 mg, 1 times / day Route: respiratory Route: multiple Dose: 590 mg, 1 times / day Sources: |
unhealthy, 58.0 years (range: 16 - 61 years) n = 44 Health Status: unhealthy Age Group: 58.0 years (range: 16 - 61 years) Sex: M+F Population Size: 44 Sources: |
Pneumonia | 1 patient Disc. AE |
590 mg 1 times / day multiple, respiratory Recommended Dose: 590 mg, 1 times / day Route: respiratory Route: multiple Dose: 590 mg, 1 times / day Sources: |
unhealthy, 58.0 years (range: 16 - 61 years) n = 44 Health Status: unhealthy Age Group: 58.0 years (range: 16 - 61 years) Sex: M+F Population Size: 44 Sources: |
Respiratory disorder | 1 patient Disc. AE |
590 mg 1 times / day multiple, respiratory Recommended Dose: 590 mg, 1 times / day Route: respiratory Route: multiple Dose: 590 mg, 1 times / day Sources: |
unhealthy, 58.0 years (range: 16 - 61 years) n = 44 Health Status: unhealthy Age Group: 58.0 years (range: 16 - 61 years) Sex: M+F Population Size: 44 Sources: |
Dyspnea | 4.5% Disc. AE |
590 mg 1 times / day multiple, respiratory Recommended Dose: 590 mg, 1 times / day Route: respiratory Route: multiple Dose: 590 mg, 1 times / day Sources: |
unhealthy, 58.0 years (range: 16 - 61 years) n = 44 Health Status: unhealthy Age Group: 58.0 years (range: 16 - 61 years) Sex: M+F Population Size: 44 Sources: |
Infective exacerbation of bronchiectasis | 6.8% Disc. AE |
590 mg 1 times / day multiple, respiratory Recommended Dose: 590 mg, 1 times / day Route: respiratory Route: multiple Dose: 590 mg, 1 times / day Sources: |
unhealthy, 58.0 years (range: 16 - 61 years) n = 44 Health Status: unhealthy Age Group: 58.0 years (range: 16 - 61 years) Sex: M+F Population Size: 44 Sources: |
Bronchospasm | 590 mg 1 times / day multiple, respiratory Recommended Dose: 590 mg, 1 times / day Route: respiratory Route: multiple Dose: 590 mg, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
|
Hemoptysis | 590 mg 1 times / day multiple, respiratory Recommended Dose: 590 mg, 1 times / day Route: respiratory Route: multiple Dose: 590 mg, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
|
Hypersensitivity pneumonitis | 590 mg 1 times / day multiple, respiratory Recommended Dose: 590 mg, 1 times / day Route: respiratory Route: multiple Dose: 590 mg, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
[Evaluation of ototoxicity of amikacin (BB-K8) by animal test (author's transl)]. | 1975 Jun |
|
Antimicrobial susceptibility of Mycobacterium marinum determined by E-test and agar dilution. | 2001 |
|
Occurrence of variants with temperature-dependent susceptibility (TDS) to antibiotics among Stenotrophomonas maltophilia clinical strains. | 2001 |
|
[Criteria of low risk of mortality in children with neutropenia and fever during cancer chemotherapy]. | 2001 |
|
Molecular diagnosis of a Mycobacterium chelonae infection. | 2001 |
|
Antimicrobial effect of protein(s) isolated from a marine mollusc Telescopium telescopium. | 2001 Apr |
|
Aeromonas sobria sepsis in a neutropenic patient. | 2001 Apr |
|
[Combination therapy of antibiotics and intravenous immunoglobulin]. | 2001 Apr |
|
Oral ciprofloxacin in the management of children with cancer with lower risk febrile neutropenia. | 2001 Apr 15 |
|
Monotherapy with meropenem versus combination therapy with piperacillin plus amikacin as empiric therapy for neutropenic fever in children with lymphoma and solid tumors. | 2001 Apr-Jun |
|
Urinary excretion reflects lung deposition of aminoglycoside aerosols in cystic fibrosis. | 2001 Aug |
|
Comparison of 2 techniques for regional antibiotic delivery to the equine forelimb: intraosseous perfusion vs. intravenous perfusion. | 2001 Aug |
|
Optimizing antibiotic therapy in the intensive care unit setting. | 2001 Aug |
|
Serum pharmacokinetics and sputum penetration of amikacin 30 mg/kg once daily and of ceftazidime 200 mg/kg/day as a continuous infusion in cystic fibrosis patients. | 2001 Aug |
|
Role of megalin in renal handling of aminoglycosides. | 2001 Aug |
|
[Antibiotic resistance of Staphylococcus aureus in urban experience: 6 month study in Aquitaine]. | 2001 Feb |
|
[Correlation between sensitivity to fosfomycin and the presence of penicillinase PSE-1 in Pseudomonas aeruginosa]. | 2001 Feb |
|
Objective method for differentiating between drug-induced vestibulotoxicity and cochleotoxicity. | 2001 Jan |
|
Prevalence and characteristics of Pasteurella multocida in commercial turkeys. | 2001 Jan-Mar |
|
Changes in electrovestibular brainstem responses after aminoglycoside intoxication in guinea pigs. | 2001 Jul |
|
Intravitreal antibiotics: the emergency kit. | 2001 Jul |
|
Treatment and outcome of nocardia keratitis. | 2001 Jul |
|
Penetration of amikacin into aqueous humor of rabbits. | 2001 Jul-Aug |
|
In vitro effect of amikacin, imipenem, cefodizime, IFNalpha-2a alone and combinations of antibiotics with IFNalpha-2a on polymorphonuclear leukocyte function in chronic hepatitis patients. | 2001 Jul-Aug |
|
Antibiotic susceptibility and phage typing of methicillin-resistant and -sensitive Staphylococcus aureus clinical isolates at three periods during 1991-1997. | 2001 Jun |
|
Blood stream infections in a medical intensive care unit: spectrum and antibiotic susceptibility pattern. | 2001 Jun |
|
[Neonatal bacterial infections at the CUH of Dakar]. | 2001 Jun |
|
Cost-effectiveness of cefepime + netilmicin or ceftazidime + amikacin or meropenem monotherapy in febrile neutropenic children with malignancy in Turkey. | 2001 Jun |
|
Antibiotic resistance among Gram-negative non-fermentative bacteria at a teaching hospital in Saudi Arabia. | 2001 Jun |
|
Changing antibiotic sensitivity patterns at a university hospital, 1992 through 1999. | 2001 Jun |
|
Madura foot: treatment of Nocardia nova infection with antibiotics alone. | 2001 Jun |
|
The early bactericidal activity of amikacin in pulmonary tuberculosis. | 2001 Jun |
|
Antimicrobial susceptibility of Pseudomonas aeruginosa: results of a UK survey and evaluation of the British Society for Antimicrobial Chemotherapy disc susceptibility test. | 2001 Jun |
|
Retinal vasculitis and posterior pole "hypopyons" as early signs of acute bacterial endophthalmitis. | 2001 Jun |
|
Nephrotoxicants induce endothelin release and signaling in renal proximal tubules: effect on drug efflux. | 2001 Jun |
|
Mycobacterium fortuitum wound infection following laparoscopy. | 2001 Mar |
|
Study on antimicrobial susceptibility of bacteria causing neonatal infections: a 12 year study (1987-1998). | 2001 Mar |
|
Efficacy and tolerability of piperacillin/tazobactam versus ceftazidime in association with amikacin for treating nosocomial pneumonia in intensive care patients: a prospective randomized multicenter trial. | 2001 Mar |
|
Characterization of nonfermenters from clinical samples. | 2001 Mar |
|
Treatment of nosocomial postoperative pneumonia in cancer patients: a prospective randomized study. | 2001 Mar |
|
[Mycobacterium xenopi: epidemiological and bacteriological features]. | 2001 Mar-Apr |
|
Ocular nocardia infections with special emphasis on the cornea. | 2001 Mar-Apr |
|
[Functional characterization of a multiple-antibiotic resistant plasmid from clinical isolates of methicillin-resistant Staphylococcus aureus]. | 2001 May |
|
Streptococcus agalactiae endocarditis and giant pyomyoma simulating ovarian cancer. | 2001 May |
|
In vitro susceptibility to 15 antibiotics of vibrios isolated from penaeid shrimps in Northwestern Mexico. | 2001 May |
|
In vivo efficacy of continuous infusion versus intermittent dosing of ceftazidime alone or in combination with amikacin relative to human kinetic profiles in a Pseudomonas aeruginosa rabbit endocarditis model. | 2001 May |
|
Clinical applications of a novel sustained-release injectable drug delivery system: DepoFoam technology. | 2001 May-Jun |
|
Liposome-encapsulated aminoglycosides in pre-clinical and clinical studies. | 2001 Sep |
|
A simple tool for monitoring nebulized amikacin treatments based on a single urine assay. | 2001 Spring |
|
Trends in antimicrobial resistance of Salmonella isolated from animals, foods of animal origin, and the environment of animal production in Canada, 1994-1997. | 2001 Summer |
Sample Use Guides
In Vivo Use Guide
Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6ec3129b-c53b-4bdb-913d-a2d0060fa140
Curator's Comment: Intravenous Administration
The individual dose, the total daily dose, and the total cumulative dose of amikacin sulfate are identical to the dose recommended for intramuscular administration. The solution for intravenous use is prepared by adding the contents of a 500 mg vial to 100 or 200 mL of sterile diluent such as 0.9% sodium chloride injection or 5% dextrose injection or any other compatible solutions listed below. The solution is administered to adults over a 30 to 60 minute period. The total daily dose should not exceed 15 mg/kg/day and may be divided into either 2 or 3 equally-divided doses at equally-divided intervals.
Amikacin can also be given by inhalation - The usual dose for adults with CF is 250-500mg twice a day via nebulizer. http://torontoadultcf.com/medications/inhaled-amikacin
The recommended dosage for adults, children and older infants with normal renal function is 15 mg/kg/day divided into 2 or 3 equal doses administered at equally divided intervals, i.e., 7.5 mg/kg q12h or 5 mg/kg q8h. Treatment of patients in the heavier weight classes should not exceed 1.5 grams/day.
When amikacin is indicated in newborns, it is recommended that a loading dose of 10 mg/kg be administered initially to be followed with 7.5 mg/kg every 12 hours. The usual duration of treatment is 7 to 10 days. It is desirable to limit the duration of treatment to short-term whenever feasible. The total daily dose by all routes of administration should not exceed 15 mg/kg/day.
Route of Administration:
Intramuscular
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/26855743
Curator's Comment: Eight P. aeruginosa isolates obtained from clinical samples of burned patients and standard strain ATCC 27853 were used. Amikacin at 4 ug/mL concentration induced lower rate of coccoid bacteria (55.05%). Amikacin had a strong bactericidal effect on coccoid bacteria at 8 ug/mL concentration.
Amikacin had a strong bactericidal effect on coccoid bacteria at 8 ug/mL concentration.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:06:41 UTC 2023
by
admin
on
Fri Dec 15 15:06:41 UTC 2023
|
Record UNII |
84319SGC3C
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000175477
Created by
admin on Fri Dec 15 15:06:41 UTC 2023 , Edited by admin on Fri Dec 15 15:06:41 UTC 2023
|
||
|
CFR |
21 CFR 522.56
Created by
admin on Fri Dec 15 15:06:41 UTC 2023 , Edited by admin on Fri Dec 15 15:06:41 UTC 2023
|
||
|
WHO-ATC |
D06AX12
Created by
admin on Fri Dec 15 15:06:41 UTC 2023 , Edited by admin on Fri Dec 15 15:06:41 UTC 2023
|
||
|
FDA ORPHAN DRUG |
342011
Created by
admin on Fri Dec 15 15:06:41 UTC 2023 , Edited by admin on Fri Dec 15 15:06:41 UTC 2023
|
||
|
WHO-VATC |
QJ01GB06
Created by
admin on Fri Dec 15 15:06:41 UTC 2023 , Edited by admin on Fri Dec 15 15:06:41 UTC 2023
|
||
|
LIVERTOX |
NBK548695
Created by
admin on Fri Dec 15 15:06:41 UTC 2023 , Edited by admin on Fri Dec 15 15:06:41 UTC 2023
|
||
|
NDF-RT |
N0000007853
Created by
admin on Fri Dec 15 15:06:41 UTC 2023 , Edited by admin on Fri Dec 15 15:06:41 UTC 2023
|
||
|
FDA ORPHAN DRUG |
217305
Created by
admin on Fri Dec 15 15:06:41 UTC 2023 , Edited by admin on Fri Dec 15 15:06:41 UTC 2023
|
||
|
WHO-VATC |
QD06AX12
Created by
admin on Fri Dec 15 15:06:41 UTC 2023 , Edited by admin on Fri Dec 15 15:06:41 UTC 2023
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
6.2.4
Created by
admin on Fri Dec 15 15:06:41 UTC 2023 , Edited by admin on Fri Dec 15 15:06:41 UTC 2023
|
||
|
FDA ORPHAN DRUG |
507715
Created by
admin on Fri Dec 15 15:06:41 UTC 2023 , Edited by admin on Fri Dec 15 15:06:41 UTC 2023
|
||
|
CFR |
21 CFR 862.3035
Created by
admin on Fri Dec 15 15:06:41 UTC 2023 , Edited by admin on Fri Dec 15 15:06:41 UTC 2023
|
||
|
WHO-ATC |
J01GB06
Created by
admin on Fri Dec 15 15:06:41 UTC 2023 , Edited by admin on Fri Dec 15 15:06:41 UTC 2023
|
||
|
FDA ORPHAN DRUG |
282109
Created by
admin on Fri Dec 15 15:06:41 UTC 2023 , Edited by admin on Fri Dec 15 15:06:41 UTC 2023
|
||
|
WHO-ATC |
S01AA21
Created by
admin on Fri Dec 15 15:06:41 UTC 2023 , Edited by admin on Fri Dec 15 15:06:41 UTC 2023
|
||
|
WHO-ATC |
J01RA06
Created by
admin on Fri Dec 15 15:06:41 UTC 2023 , Edited by admin on Fri Dec 15 15:06:41 UTC 2023
|
||
|
NCI_THESAURUS |
C2363
Created by
admin on Fri Dec 15 15:06:41 UTC 2023 , Edited by admin on Fri Dec 15 15:06:41 UTC 2023
|
||
|
WHO-VATC |
QS01AA21
Created by
admin on Fri Dec 15 15:06:41 UTC 2023 , Edited by admin on Fri Dec 15 15:06:41 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
AMIKACIN
Created by
admin on Fri Dec 15 15:06:41 UTC 2023 , Edited by admin on Fri Dec 15 15:06:41 UTC 2023
|
PRIMARY | Description: White or almost white powder. Solubility: Freely soluble in water, practically insoluble in acetone R or ethanol (~750 g/l) TS. Category: Antibacterial. Storage: Amikacin should be kept in a tightly closed container, or if sterile, in a hermetically closed container. Labelling: The label states:- where applicable, that the substances is free from bacterial endotoxins,- where applicable, that the substance is sterile. Definition: Amikacin is a semi-synthetic product derived from a fermentation product, kanamycin A. Amikacin contains not less than 96.5% and not more than 102.0% (Assay, Method A) or not less than 98.5% and not more than 101.0% (Assay, Method B) of amikacin (C22H43N5O13), calculated with reference to the anhydrous substance. | ||
|
C61615
Created by
admin on Fri Dec 15 15:06:41 UTC 2023 , Edited by admin on Fri Dec 15 15:06:41 UTC 2023
|
PRIMARY | |||
|
157
Created by
admin on Fri Dec 15 15:06:41 UTC 2023 , Edited by admin on Fri Dec 15 15:06:41 UTC 2023
|
PRIMARY | |||
|
AMIKACIN
Created by
admin on Fri Dec 15 15:06:41 UTC 2023 , Edited by admin on Fri Dec 15 15:06:41 UTC 2023
|
PRIMARY | |||
|
CHEMBL177
Created by
admin on Fri Dec 15 15:06:41 UTC 2023 , Edited by admin on Fri Dec 15 15:06:41 UTC 2023
|
PRIMARY | |||
|
37517-28-5
Created by
admin on Fri Dec 15 15:06:41 UTC 2023 , Edited by admin on Fri Dec 15 15:06:41 UTC 2023
|
PRIMARY | |||
|
1019508
Created by
admin on Fri Dec 15 15:06:41 UTC 2023 , Edited by admin on Fri Dec 15 15:06:41 UTC 2023
|
PRIMARY | |||
|
100000092483
Created by
admin on Fri Dec 15 15:06:41 UTC 2023 , Edited by admin on Fri Dec 15 15:06:41 UTC 2023
|
PRIMARY | |||
|
D000583
Created by
admin on Fri Dec 15 15:06:41 UTC 2023 , Edited by admin on Fri Dec 15 15:06:41 UTC 2023
|
PRIMARY | |||
|
3583
Created by
admin on Fri Dec 15 15:06:41 UTC 2023 , Edited by admin on Fri Dec 15 15:06:41 UTC 2023
|
PRIMARY | |||
|
DTXSID3022586
Created by
admin on Fri Dec 15 15:06:41 UTC 2023 , Edited by admin on Fri Dec 15 15:06:41 UTC 2023
|
PRIMARY | |||
|
253-538-5
Created by
admin on Fri Dec 15 15:06:41 UTC 2023 , Edited by admin on Fri Dec 15 15:06:41 UTC 2023
|
PRIMARY | |||
|
84319SGC3C
Created by
admin on Fri Dec 15 15:06:41 UTC 2023 , Edited by admin on Fri Dec 15 15:06:41 UTC 2023
|
PRIMARY | |||
|
177001
Created by
admin on Fri Dec 15 15:06:41 UTC 2023 , Edited by admin on Fri Dec 15 15:06:41 UTC 2023
|
PRIMARY | |||
|
37768
Created by
admin on Fri Dec 15 15:06:41 UTC 2023 , Edited by admin on Fri Dec 15 15:06:41 UTC 2023
|
PRIMARY | |||
|
Amikacin
Created by
admin on Fri Dec 15 15:06:41 UTC 2023 , Edited by admin on Fri Dec 15 15:06:41 UTC 2023
|
PRIMARY | |||
|
SUB05431MIG
Created by
admin on Fri Dec 15 15:06:41 UTC 2023 , Edited by admin on Fri Dec 15 15:06:41 UTC 2023
|
PRIMARY | |||
|
3492
Created by
admin on Fri Dec 15 15:06:41 UTC 2023 , Edited by admin on Fri Dec 15 15:06:41 UTC 2023
|
PRIMARY | |||
|
641
Created by
admin on Fri Dec 15 15:06:41 UTC 2023 , Edited by admin on Fri Dec 15 15:06:41 UTC 2023
|
PRIMARY | RxNorm | ||
|
2637
Created by
admin on Fri Dec 15 15:06:41 UTC 2023 , Edited by admin on Fri Dec 15 15:06:41 UTC 2023
|
PRIMARY | |||
|
DB00479
Created by
admin on Fri Dec 15 15:06:41 UTC 2023 , Edited by admin on Fri Dec 15 15:06:41 UTC 2023
|
PRIMARY | |||
|
m1670
Created by
admin on Fri Dec 15 15:06:41 UTC 2023 , Edited by admin on Fri Dec 15 15:06:41 UTC 2023
|
PRIMARY | Merck Index | ||
|
84319SGC3C
Created by
admin on Fri Dec 15 15:06:41 UTC 2023 , Edited by admin on Fri Dec 15 15:06:41 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
BINDER->LIGAND |
BINDING
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT | |||
|
IMPURITY -> PARENT |
Amikacin is a semi-synthetic product derived from a fermentation product, kanamycin A. Amikacin contains not less than 96.5% and not more than 102.0% (Assay, Method A) or not less than 98.5% and not more than 101.0% (Assay, Method B) of amikacin (C22H43N5O13), calculated with reference to the anhydrous substance.
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Volume of Distribution | PHARMACOKINETIC |
|
|
|||
Biological Half-life | PHARMACOKINETIC |
|
|
|||